Skip directly to searchSkip directly to the site navigationSkip directly to the page's main content

Cancer Incidence - Prostate Cancer

Summary Indicator Report Data View Options

New Prostate Cancer Cases per 100,000 Population (Males) by County, New Mexico, 2011-2015

New Prostate Cancer Cases per 100,000 Population (Males) by Health Region, New Mexico, 2011-2015

New Prostate Cancer Cases per 100,000 Population (Males) by Urban and Rural Counties, New Mexico, 2011-2015

New Prostate Cancer Cases per 100,000 Population (Males) by U.S. States, 2015

Why Is This Important?

In New Mexico, prostate cancer is the most commonly diagnosed cancer for African American, Asian, Hispanic and White men, and is the second most commonly diagnosed cancer for American Indian men. Prostate cancer is the leading cause of death from cancer for American Indian men, the second leading cause of death from cancer for African American and White men, and is the third leading cause of cancer death for Asian and Hispanic men in New Mexico.

Definition

New cases of prostate cancer per 100,000 population (males) in New Mexico Prostate cancer incidence is defined as new cases of malignant cancer of the prostate.

Data Sources

How the Measure is Calculated

Numerator:Number of new prostate cancer cases in New Mexico
Denominator:New Mexico male population

How Are We Doing?

The rate of new cases of prostate cancer among New Mexican men has continued to decline over the past decade after having been stable since the mid-1990s.

What Is Being Done?

According to the Centers for Disease Control and Prevention (CDC), we need better ways to screen for and treat prostate cancer. Until these discoveries are made, and even when they are, men and their families should turn to trusted health care professionals to help them make informed decisions. If you are thinking about being screened, you and your doctor should consider: - If you have a family history of prostate cancer - If you are African-American - If you have other medical conditions that may make it difficult for you to be treated for prostate cancer if it is found, or that may make you less likely to benefit from screening - How you value the potential benefits and harms of screening, diagnosis, and treatment

Evidence-based Practices

The Comprehensive Cancer Program (CCP) promotes screening recommendations made by the US Preventive Services Task Force (USPSTF). In 2018, the USPSTF concluded that for men ages 55 to 69 years, the decision to undergo periodic prostate-specific antigen (PSA)based screening for prostate cancer should be an individual one. Before deciding whether to be screened, men should have an opportunity to discuss the potential benefits and harms of screening with their clinician and to incorporate their values and preferences in the decision. Screening offers a small potential benefit of reducing the chance of death from prostate cancer in some men. However, many men will experience potential harms of screening, including false-positive results that require additional testing and possible prostate biopsy; overdiagnosis and overtreatment; and treatment complications, such as incontinence and erectile dysfunction. In determining whether this service is appropriate in individual cases, patients and clinicians should consider the balance of benefits and harms on the basis of family history, race/ethnicity, comorbid medical conditions, patient values about the benefits and harms of screening and treatment-specific outcomes, and other health needs. Clinicians should not screen men who do not express a preference for screening.

Available Services

Please visit the New Mexico Department of Health Comprehensive Cancer Program website at: http://archive.cancernm.org/ccp/

More Resources

New Mexico Department of Health Comprehensive Cancer Program (http://archive.cancernm.org/ccp/) United States Preventive Services Task Force (USPSTF) (https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/prostate-cancer-screening1) Centers for Disease Control and Prevention (CDC) (http://www.cdc.gov/cancer/prostate/index.htm) Surveillance Epidemiology and End Result (SEER) Program (http://seer.cancer.gov/) New Mexico Tumor Registry (NMTR), University of New Mexico Health Sciences Center, School of Medicine (http://nmtrweb.unm.edu/) National Cancer Institute (NCI) (www.cancer.gov) American Cancer Society (ACS) (www.cancer.org) New Mexico Cancer Council (NMCC) (http://www.nmcancercouncil.org/) Albuquerque Cancer Coalition (ACC) (https://acc.nmcca.org/) The National Library of Medicine (NLM) MedlinePlus (www.medlineplus.gov) Commission on Cancer (www.facs.org/quality-programs/cancer) Cancer Control P.L.A.N.E.T. (http://cancercontrolplanet.cancer.gov/) The Guide to Community Preventive Services (http://www.thecommunityguide.org/cancer/index.html) Research-tested Intervetion Programs (RTIPs) (http://rtips.cancer.gov/rtips/index.do)

Health Program Information

Visit the New Mexico Department of Health Comprehensive Cancer Program website at: http://archive.cancernm.org/ccp/

Indicator Data Last Updated On 01/03/2019, Published on 01/07/2019
Cancer Prevention and Control Section, Population and Community Health Bureau, Public Health Division, New Mexico Department of Health, 5301 Central Ave. NE, Suite 800, Albuquerque, NM 87108, Telephone: (505) 841-5840. For data inquiries, contact the Cancer Section Epidemiologist, Libby Bruggeman, PhD, MA (email: Libby.Bruggeman@state.nm.us) or the Medical Officer/Epidemiologist, Susan Baum, MD, MPH (email: susan.baum@state.nm.us).